Which ETFs hold IONS? Ionis Pharmaceuticals Inc is held by 1 fund tracked by ETFpeek.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 31 Jul 2026 | Michael R Hayden Director / Other | BUY | Discretionary | 5,000 | $258K | 80 |
| 30 Jul 2026 | Michael R Hayden Director / Other | BUY | Discretionary | 15,000 | $801K | 100 |
| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 31 Jul 2026 | Michael R Hayden Director / Other | BUY | Discretionary | 5,000 | $258K | 80 |
| 30 Jul 2026 | Michael R Hayden Director / Other | BUY | Discretionary | 15,000 | $801K | 100 |
| 15 Jul 2026 | Peter N Reikes Director / Other | BUY | Vested (RSU) | 3,399 | — | 30 |
| 15 Jul 2026 | Ludwig Hantson Director / Other | BUY | Vested (RSU) | 3,399 | — | 30 |
| 15 Jul 2026 | Joan E Herman Director / Other | BUY | Option Exercise | 5,220 | — | 30 |
| 15 Jul 2026 | Spencer R Berthelsen Director / Other | BUY | Option Exercise | 5,220 | — | 30 |
| Date | Fund | Direction | Shares Changed | % Δ ETF | % Δ Position |
|---|---|---|---|---|---|
| 22 Sep 2026 | ARKG | BUYAdded | +100,246 | +0.21% | 11.35% |
| 15 Sep 2026 | ARKG | BUYAdded | +166,580 | +0.33% | 22.30% |
| 20 Aug 2026 | ARKG | BUYAdded | +18,484 | -0.08% | 3.16% |
| 19 Aug 2026 | ARKG | BUYAdded | +26,246 | +0.15% | 4.76% |
| 18 Aug 2026 | ARKG | BUYAdded | +6,839 | +0.05% | 1.30% |
| 15 Jul 2026 | ARKG | BUYAdded | +49,004 | +0.10% | 9.31% |
| 14 Jul 2026 | ARKG | BUYAdded | +66,278 | +0.22% | 13.85% |
| 13 Jul 2026 | ARKG | BUYAdded | +28,035 | +0.01% | 6.79% |
| 10 Jul 2026 | ARKG | BUYAdded | +105,364 | +0.03% | 27.35% |
| No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal. | |||||